Aviptidil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Status:
COMPLETED
Trial end date:
2022-11-20
Target enrollment:
Participant gender:
Summary
This study looks at the safety and effectiveness of Aviptidil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Aviptidil plus current standard of care (SOC), or with placebo plus current SOC.
Phase:
PHASE3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Kirby Institute Medical Research Council NeuroRx, Inc. Prevention and Early Treatment of Acute Lung Injury (PETAL) Network University of Copenhagen US Department of Veterans Affairs Washington D.C. Veterans Affairs Medical Center